Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition

Since the outbreak of the COVID-19 pandemic in December 2019 and its rapid spread worldwide, the scientific community has been under pressure to react and make progress in the development of an effective treatment against the virus responsible for the disease. Here, we implement an original virtual screening (VS) protocol for repositioning approved drugs in order to predict which of them could inhibit the main protease of the virus (M-pro), a key target for antiviral drugs given its essential role in the virus’ replication. Two different libraries of approved drugs were docked against the structure of M-pro using Glide, FRED and AutoDock Vina, and only the equivalent high affinity binding modes predicted simultaneously by the three docking programs were considered to correspond to bioactive poses. In this way, we took advantage of the three sampling algorithms to generate hypothetic binding modes without relying on a single scoring function to rank the results. Seven possible SARS-CoV-2 M-pro inhibitors were predicted using this approach: Perampanel, Carprofen, Celecoxib, Alprazolam, Trovafloxacin, Sarafloxacin and ethyl biscoumacetate. Carprofen and Celecoxib have been selected by the COVID Moonshot initiative for in vitro testing; they show 3.97 and 11.90% M-pro inhibition at 50 µM, respectively.

[1]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[2]  J. Tuszynski,et al.  Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design , 2020, International journal of molecular sciences.

[3]  M. U. Mirza,et al.  Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase , 2020, Journal of Pharmaceutical Analysis.

[4]  Hualiang Jiang,et al.  Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease , 2020, Science.

[5]  P. Procacci,et al.  Identification of potential binders of the main protease 3CLpro of the COVID-19 via structure-based ligand design and molecular modeling , 2020, Chemical Physics Letters.

[6]  Hualiang Jiang,et al.  Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.

[7]  B. Salim.  Identification of Compounds from Nigella Sativa as New Potential Inhibitors of 2019 Novel Coronasvirus (Covid-19): Molecular Docking Study , 2020 .

[8]  N. Missoum,et al.  Identification of Compounds from Nigella Sativa as New Potential Inhibitors of 2019 Novel Coronasvirus (Covid-19): Molecular Docking Study , 2020 .

[9]  Xin Wang,et al.  FEP-based screening prompts drug repositioning against COVID-19 , 2020 .

[10]  A. Mesecar,et al.  Structure of COVID-19 main protease bound to potent broad-spectrum non-covalent inhibitor X77 , 2020 .

[11]  M. Sekijima,et al.  Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates , 2020, Scientific Reports.

[12]  V. Eyupoglu,et al.  Identification of Potent COVID-19 Main Protease (Mpro) Inhibitors from Natural Polyphenols: An in Silico Strategy Unveils a Hope against CORONA , 2020 .

[13]  R. Hilgenfeld,et al.  Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors , 2020, Science.

[14]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[15]  R. Awaluddin,et al.  Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study , 2020 .

[16]  Dong Xu,et al.  AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2 , 2020, bioRxiv.

[17]  M. U. Mirza,et al.  Structural Elucidation of SARS-CoV-2 Vital Proteins: Computational Methods Reveal Potential Drug Candidates Against Main Protease, Nsp12 RNA-dependent RNA Polymerase and Nsp13 Helicase , 2020 .

[18]  J. Tuszynski,et al.  Structural and Evolutionary Analysis Indicate that the SARS-CoV-2 Mpro is an Inconvenient Target for Small-Molecule Inhibitors Design , 2020, medRxiv.

[19]  Ming Liu,et al.  COVID-19 Docking Server: An interactive server for docking small molecules, peptides and antibodies against potential targets of COVID-19 , 2020, 2003.00163.

[20]  Massoud Amanlou,et al.  Simeprevir, Potential Candidate to Repurpose for Coronavirus Infection: Virtual Screening and Molecular Docking Study , 2020 .

[21]  Yechun Xu,et al.  Structure of Mpro from COVID-19 virus and discovery of its inhibitors , 2020, bioRxiv.

[22]  P. Procacci,et al.  Inhibition of the Main Protease 3CL-pro of the Coronavirus Disease 19 via Structure-Based Ligand Design and Molecular Modeling , 2020, 2002.09937.

[23]  F. Ban,et al.  Rapid Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease by Deep Docking of 1.3 Billion Compounds , 2020, Molecular informatics.

[24]  E. Dong,et al.  An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.

[25]  Jianxing Song.  2019-nCoV 3C-Like Protease carries an activity-enhancing T285 /A variation which may contribute to its high infectivity , 2020 .

[26]  Yu Wai Chen,et al.  Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like Protease (3CLpro) Structure: Virtual Screening Reveals Velpatasvir, Ledipasvir, and Other Drug Repurposing Candidates , 2020 .

[27]  Xiu-Jie Wang,et al.  Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines , 2020, Journal of Genetics and Genomics.

[28]  Gengfu Xiao,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[29]  Weiliang Zhu,et al.  Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation , 2020, bioRxiv.

[30]  Pedro H M Torres,et al.  Key Topics in Molecular Docking for Drug Design , 2019, International journal of molecular sciences.

[31]  Ailing Fu,et al.  An Overview of Scoring Functions Used for Protein–Ligand Interactions in Molecular Docking , 2019, Interdisciplinary Sciences: Computational Life Sciences.

[32]  Adrià Cereto-Massagué,et al.  The Light and Dark Sides of Virtual Screening: What Is There to Know? , 2019, International journal of molecular sciences.

[33]  Dominique Douguet,et al.  Data Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs. , 2018, ACS medicinal chemistry letters.

[34]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[35]  Liliane Mouawad,et al.  Efficient conformational sampling and weak scoring in docking programs? Strategy of the wisdom of crowds , 2017, Journal of Cheminformatics.

[36]  P. Duhaut,et al.  Non-steroidal Anti-inflammatory Drugs may Worsen the Course of Community-Acquired Pneumonia: A Cohort Study , 2017, Lung.

[37]  Marjana Novič,et al.  The Comparison of Docking Search Algorithms and Scoring Functions: An Overview and Case Studies , 2016 .

[38]  John J. Irwin,et al.  ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..

[39]  K. Pillai,et al.  Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity , 2014, Expert opinion on drug metabolism & toxicology.

[40]  Weida Tong,et al.  In silico drug repositioning: what we need to know. , 2013, Drug discovery today.

[41]  Mark McGann,et al.  FRED Pose Prediction and Virtual Screening Accuracy , 2011, J. Chem. Inf. Model..

[42]  Jan H. Jensen,et al.  PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.

[43]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[44]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[45]  Wei Zhao,et al.  Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase , 2009, J. Chem. Inf. Model..

[46]  Angel Herráez,et al.  Biomolecules in the computer: Jmol to the rescue , 2006, Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology.

[47]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[48]  K. Shadan,et al.  Available online: , 2012 .